Michael T. Hemann

Dr. Hemann's group has made extensive use of mice as preclinical systems to examine therapeutic efficacy and have developed hematopoietic and solid tumor models that can effectively interrogate aspects of acquired and intrinsic drug resistance. This also involves the use of computational approaches to examine tumor heterogeneity and evolution. His work has pioneered the development of novel screening strategies to characterize the genetic determinants of drug action in relevant physiological settings.  These systems are highly tractable, such that one can rapidly progress from candidate gene identification to cell-based and in vivo validation experiments. We have also been able to extend this work into the clinic in the context of treatment refractory B cell malignancies. His ongoing objective is the development of combination drug regimens that can subvert the evolution of drug resistance